NCT03618186View on ClinicalTrials.gov

Neuroimaging Study

PHASE2Enrolling by invitationINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

November 26, 2018

Primary Completion Date

May 31, 2030

Study Completion Date

May 31, 2030

Conditions

Cognitive Impairment

Interventions

COMBINATION_PRODUCT

Tau PET scan

Patient will receive a dose of flutaucipir and be scanned appropriately

Trial Locations (2)

32224

Mayo Clinic in Florida, Jacksonville

55905

Mayo Clinic Minnesota, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

National Institute on Aging (NIA)

NIH

lead

Mayo Clinic

OTHER